Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Epoprostenol
Drug ID BADD_D00788
Description A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Indications and Usage For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Marketing Status approved
ATC Code B01AC09
DrugBank ID DB01240
KEGG ID D00106
MeSH ID D011464
PubChem ID 5282411
TTD Drug ID D0V0IX
NDC Product Code 66215-402; 62756-060; 66215-403; 62287-123; 62756-059
UNII DCR9Z582X0
Synonyms Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 35121-78-9
SMILES CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Terminal state08.01.03.0790.000123%-
Live birth18.08.02.0070.000403%-
Spinal cord ischaemia17.10.01.018; 24.04.06.0400.000329%-
Right ventricular hypertrophy02.04.02.0340.000082%-
Portal hypertensive gastropathy07.12.01.007; 09.01.06.022; 24.08.06.0060.000082%-
Right ventricular dysfunction02.04.02.0330.000082%
Arterial haemorrhage24.07.01.0630.000082%-
Acute right ventricular failure02.05.03.0030.000082%-
Delivery18.08.02.0060.000123%-
Internal haemorrhage24.07.01.0720.000164%-
Administration site odour08.02.04.027; 12.07.04.0270.000181%-
Catheter site dermatitis08.02.02.015; 12.07.02.015; 23.03.04.0430.000082%-
Catheter site discharge08.02.02.016; 12.07.02.0160.001308%-
Catheter site discolouration08.02.02.017; 12.07.02.017; 23.03.03.0740.000181%-
Catheter site irritation08.02.02.022; 12.07.02.0220.000123%-
Catheter site pruritus08.02.02.025; 12.07.02.025; 23.03.12.0110.001933%-
Catheter site rash08.02.02.026; 12.07.02.026; 23.03.13.0240.000748%-
Catheter site scab08.02.02.027; 12.07.02.027; 23.03.03.0750.000222%-
Catheter site swelling08.02.02.005; 12.07.02.0050.000921%-
Catheter site vesicles08.02.02.030; 12.07.02.030; 23.03.01.0320.000485%-
Catheter site warmth08.02.02.031; 12.07.02.0310.000123%-
Coronary artery compression02.02.01.018; 12.02.01.034; 24.04.04.0290.000082%-
Disease complication08.01.03.0870.000288%-
Endocrine ophthalmopathy05.02.02.008; 06.09.04.008; 10.04.08.012; 14.11.01.0510.000082%-
Graves' disease05.02.02.009; 06.09.04.009; 10.04.08.0140.000452%-
Illness08.01.03.0910.000304%-
Infusion site discolouration08.02.05.026; 12.07.05.026; 23.03.03.0840.000082%-
Lid lag05.02.01.006; 06.05.01.006; 17.17.02.0160.000082%-
Lung opacity22.12.01.0060.000123%-
Plethoric face08.01.03.097; 23.03.03.095; 24.03.04.0170.000082%-
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages